Thymus Carcinoma (Thymic and Thymoma)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    EGFR Overexpression 69 (1) Gefitinib (EGFR inhibitor):
    • Phase II: RR 4%, SD ≥ 4 mo 23% (2)
    Erlotinib (EGFR inhibitor):
    • Phase II: RR 0%, SD 60% in combination with bevacizumab (VEGF inhibitor) (3)
    Cetuximab (EGFR inhibitor):
    • Case report: PR in 2 thymoma pts (after 3 mo of therapy (4)), PR (>12 mo) in 1 thymoma pt (5)
    KIT Mutation 7 Imatinib (KIT inhibitor):
    • Phase 2: SD 29% thymoma pts (>38 mo in 1 p) (6)
    • Case PR (6 mo) in 1 thymoma pt (7)
    Other topics in Targets by Organ Site